专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明授权

US11478429B2 Capsule with internal diaphragm and solid ingredients 有权
公开(公告)号：US11478429B2
公开(公告)日：2022-10-25
申请号：US15767036
申请日：2016-10-10
申请人： ComboCap, Inc.
发明人： Tobias Johan Louw
IPC分类号： A61K31/355 , A61K35/741 , A61K36/53 , A61K36/71 , A61K9/48 , A61K45/06 , A61K31/05 , A61K31/60 , A61K47/12 , A61K31/616 , A61K31/122 , A61K31/137 , A61K31/192 , A61K35/00 , A61K31/4458 , A61K31/01 , A61K31/201 , A61K31/202 , A61K31/203 , A61K31/375 , A61K31/525 , A61K33/06 , A61K33/18 , A61K33/26 , A61K33/42 , A61K31/353
摘要： A two-compartment capsule includes a body, a diaphragm between, which seals off the body and provides a first compartment to hold a first dry ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second dry ingredient. This disclosure also provides particular formulations for use in such a capsule. Examples include a probiotic, a digestive enzyme, an expectorant, a bronchodilator, a stool softener, a platelet aggregation inhibitor, a form or derivative of vitamin E, a statin, and aspirin.

72. 发明申请

US20220331403A1 METHODS AND COMPOSITIONS FOR INDUCING DIFFERENTIATION OF HUMAN BROWN ADIPOCYTE PROGENITORS 有权
公开(公告)号：US20220331403A1
公开(公告)日：2022-10-20
申请号：US17853992
申请日：2022-06-30
申请人： ENERGESIS PHARMACEUTICALS, INC.
发明人： OLIVIER D. BOSS
IPC分类号： A61K38/18 , A61K31/426 , A61K31/166 , A61K31/5415 , A61K31/165 , A61K31/4745 , A61K31/506 , A61K31/44 , A61K31/5575 , A61K31/353 , A61K38/10 , A61K38/22 , A61K38/19 , A61K38/20
摘要： This disclosure relates to compositions and methods for recruiting brown adipocytes in vitro and in vivo from brown adipocyte progenitor cells found in human skeletal muscle. Methods for treating metabolic disease are also provided. Additionally, methods for treating hypothermia are provided. In some embodiments, the brown adipocyte recruiter is a human protein or peptide. In other embodiments the brown adipocyte recruiter may be a non-human protein or peptide. In still other embodiments, the brown adipocyte recruiter is a small molecule or natural product.

73. 发明申请

US20220323464A1 COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING 有权
公开(公告)号：US20220323464A1
公开(公告)日：2022-10-13
申请号：US17531404
申请日：2021-11-19
申请人： The Brain Health Project, LLC
发明人： Morris Notelovitz
IPC分类号： A61K31/593 , A23L33/10 , A61K31/4748 , A61K31/353 , A61K31/592 , A61K31/566 , G01N33/68
摘要： The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.

74. 发明申请

US20220313673A1 DIETARY SUPPLEMENTS TO AMELIORATE DIETARY INADEQUACIES RELATED TO BRAIN HEALTH OR NEURODEGENERATIVE DISEASES, AND METHODS TO DESIGN DIETARY SUPPLEMENTS 有权
公开(公告)号：US20220313673A1
公开(公告)日：2022-10-06
申请号：US17633699
申请日：2020-08-19
申请人： NEURORESERVE INC.
发明人： Edward S. PARK , Matthew M. CRANE , John F. O'CONNELL , John C. WALLINGFORD , Elaine M. MANN
IPC分类号： A61K31/455 , A61K31/714 , A61K31/593 , A61K31/355 , A61K33/06 , A61K31/353 , A61K31/05 , A61K31/09 , A61K31/685 , A61K31/198 , A61P25/28 , A61P3/02 , A23L33/155 , A23L33/165 , A23L33/12
摘要： The dietary supplements of various embodiments comprise a water-soluble vitamin component, an oil-soluble vitamin component, magnesium or derivatives thereof, a primary polyphenolic compound, a secondary polyphenolic compound, and an omega-3-phospholipid complex. The methods include maintaining health, maintaining brain health and reducing the risk or rate of neurodegeneration or cognitive decline. Methods, including algorithms, for systematically determining a dietary supplement are also described.

75. 发明申请

US20220313171A1 Imaging and Treatment Methods for Early Detection of Diseases 有权
公开(公告)号：US20220313171A1
公开(公告)日：2022-10-06
申请号：US17221742
申请日：2021-04-02
申请人： Ishtar Faisal Algburi
发明人： Ishtar Faisal Algburi
IPC分类号： A61B5/00 , A61B5/055 , G01R33/48 , A61K49/10 , A61K45/06 , A61K33/00 , A61K31/517 , A61K31/353 , A61K49/04 , G01R33/485 , G01R33/28
摘要： This invention relates to disease detection by imaging and treatment of virus infection. Previously, there was no way to use CEST MRI imaging to early detect and map the neurodegenerative diseases, multiple sclerosis disease, concussion, and traumatic brain injury. Also, previously, there was no way to use Computed Tomography (CT) imaging to early detect and map the neurodegenerative diseases. Embodiments of the present invention use a non-invasive CEST MRI imaging method is disclosed for early detection of diseases by using MRI or by using CT. The endogenous (MRI) contrast of the biological tissue can rely on the endogenous protons of the proteins and peptides as a source of the contrast, such as hydroxyl, amine, and amide protons, and thereby provide imaging and mapping for the early detection of the neurodegenerative diseases, multiple sclerosis disease, concussion, traumatic brain injury, and other diseases by using endogenous protons contrast via CEST MRI. Also, the exogenous agents can be used to produce MRI contrast, such as agents contain exchangeable protons and thereby provide imaging and mapping the inflammation in cancer and the expressed proteins in cancer cells for cancer detection. Also, using exogenous CT contrast agents for detection of amyloid beta, tau protein, alpha-synuclein protein, and aggregation proteins in neurodegenerative diseases and inflammation in many diseases such as neurodegenerative diseases, cancer and other inflammatory diseases Also, this invention relates to novel methods of treatment virus infection and enhance the immune system to produce antibodies against the viruses.

76. 发明申请

US20220296563A1 ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE 有权
公开(公告)号：US20220296563A1
公开(公告)日：2022-09-22
申请号：US17831535
申请日：2022-06-03
申请人： Flagship Pioneering Innovations V, Inc.
发明人： John Patrick CASEY, JR. , David Arthur BERRY , Timothy F. BRIGGS , Leonard BUCKBINDER , Mi-Jeong KIM , Anna LIANG
IPC分类号： A61K31/353 , A61K31/225 , A61K31/7004 , A61P1/16
摘要： Disclosed herein are acylated active agents (e.g., acylated hydroxybenzoic acid), compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

77. 发明申请

US20220288017A1 NITENIN ANALOGUE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CHRONIC AND ACUTE PAIN 有权
公开(公告)号：US20220288017A1
公开(公告)日：2022-09-15
申请号：US17631135
申请日：2020-07-22
申请人： SEA4US - BIOTECNOLOGIA E RECURSOS MARINHOS, LDA.
发明人： Pedro Afonso DOS SANTOS BALTAZAR DE LIMA , Beatriz SZWARC DOS SANTOS , Ana Rosa MAÇO ABREU , André Emanuel PINHEIRO BASTOS , Rui GOMES , Marisa Isabel LOPES DE SOUSA , Joana Maria MONTEIRO SERRÃO , Sílvia Patrícia PENA LINO , Patrícia Isabel DA SILVEIRA MÁXIMO , Luísa Maria PINTO FERREIRA , Paula Cristina DE SÉRIO BRANCO , Henrique SOVELA MOURÃO , Vanessa Alexandra ROSADO SABINO , Ming HIM TONG , Laurent Alain CLAUDETREMBLEAU , Ana Maria FERREIRA DA COSTA LOURENÇO , Miguel Angelo SEGÃO MONDRAGÃO
IPC分类号： A61K31/365 , A61K31/353 , A61P25/04 , C07D307/28 , C07D307/36
摘要： The present disclosure relates to nitenin analogue compounds (of formulas I, II, III and IV) and their use as pharmaceutical agent in the treatment, prevention or reduction of both acute and chronic pain. The mode of action disclosed herein allows nitenin and nitenin analogue compounds to act as analgesic through reduction of K30 currents rather than their potentiation. Related to their high efficacy in the treatment of pain, these compounds are highly selective for slow voltage-activated potassium (K30 ) currents expressed in the small diameter dorsal root neurons (sDRGns), mainly on those mediated by the voltage-dependent potassium channel (KV), KV1.3. Such findings, together with those showing that nitenin and nitenin analogue compounds act as activity dependent blockers also lead to very reduced side-effects. The results disclosed herein show that nitenin and nitenin analogue compounds described herein are a viable alternative to the already existing pharmaceutical compounds used in the treatment of pain.

78. 发明申请

US20220280535A1 METHODS FOR INHIBITING MUSCLE ATROPHY 有权
公开(公告)号：US20220280535A1
公开(公告)日：2022-09-08
申请号：US17321923
申请日：2021-05-17
申请人： UNIVERSITY OF IOWA RESEARCH FOUNDATION , THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
发明人： Christopher M. ADAMS , Steven D. KUNKEL , Michael WELSH
IPC分类号： A61K31/58 , A61K31/215 , A61K31/352 , A61K31/36 , A61K31/382 , A61K31/404 , A61K31/4164 , A61K31/4166 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/4375 , A61K31/438 , A61K31/4706 , A61K31/56 , G01N33/50 , A61K31/353 , A61K31/407 , A61K31/435 , A61K31/473 , A61K31/565 , C12Q1/6809 , A61K31/436
摘要： The invention provides a method for (a) increasing skeletal muscle mass; (b) reducing skeletal muscle atrophy; (c) increasing muscular strength; (d) promoting muscle growth; (e) decreasing muscle wasting; or (f) increasing strength per unit of muscle mass in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula: or a stereoisomer, solvate, or pharmaceutically acceptable salt thereof, thereby accomplishing one or more of (a)-(f).

79. 发明授权

US11433055B2 Chromane monobactam compounds for the treatment of bacterial infections 有权
公开(公告)号：US11433055B2
公开(公告)日：2022-09-06
申请号：US16651456
申请日：2018-09-27
申请人： Merck Sharp & Dohme Corp.
发明人： Tesfaye Biftu , Xianhai Huang , Weiguo Liu , Weidong Pan , Min Park , Alexander Pasternak , Wanying Sun , Haifeng Tang , Yi Zang
IPC分类号： A61K31/353 , A61K31/397 , A61K31/427 , A61P31/04 , A61K31/4425 , A61K31/506 , A61K31/519 , C07D417/14
摘要： The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

80. 发明授权

US11420954B2 Process for the separation of gallated epicatechins (EGCG and ECG) from green tea extract or green tea dust 有权
公开(公告)号：US11420954B2
公开(公告)日：2022-08-23
申请号：US16769853
申请日：2018-11-26
申请人： CRYSTALMORPHIX TECHNOLOGIES PVT. LTD
发明人： Vamsee Krishna Muppidi , Satyanarayana Chinta
IPC分类号： C07D311/62 , A61K31/353 , A61K36/82
摘要： The present invention relates to an improved process for the separation of gallated epicatechins (EGCG & ECG) from green tea extract or green tea dust. The present invention specifically relates to an improved process for the separation of gallated epicatechins (EGCG & ECG) from green tea extract or green tea dust by forming hydrated gallated epicatechins (EGCG & ECG)-isonicotinic acid complex using isonicotinic acid as acid, organic solvents for liberating gallated epicatechins. The present invention more specifically relates to the process for the separation of gallated epicatechins (EGCG & ECG) from green tea extract or green tea dust, wherein processes comprises steps of dissolving, concentrating by centrifugation, adding, precipitating, filtering, slurrying, removing supernatant liquid, washing, extracting and freeze drying. The present invention also relates to hydrated gallated epicatechins (EGCG & ECG)-isonicotinic acid complex.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式